TECENTRIQ HYBREZA ready-to-use vial for subcutaneous injection that can be given in ~7 minutes* q3w vs 30 to 60 minutes with IV TECENTRIQ® (atezolizumab)1,2
*Refers to the injection time and does not include other aspects of treatment; actual clinic time may vary.
Watch the TECENTRIQ HYBREZA dosing and administration video for instructions on how to administer this treatment to your adult patients.
AUTOMATED VOICE: The purpose of this video is to educate healthcare professionals on how to store, prepare, and administer TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs), the first subcutaneous checkpoint inhibitor that can be administered in less than 10 minutes.
TECENTRIQ HYBREZA can be used in all adult indications in which IV TECENTRIQ (atezolizumab) has been approved.
The indications for TECENTRIQ HYBREZA can be viewed on screen.
TECENTRIQ HYBREZA is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.
Serious and sometimes fatal adverse reactions occurred with TECENTRIQ HYBREZA treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis with renal dysfunction, and solid organ transplant rejection.
Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.
Additional Important Safety Information will be shared later in this video.
For complete indication and administration information, please review the TECENTRIQ HYBREZA full Prescribing Information.
TECENTRIQ HYBREZA is a ready-to-use vial for subcutaneous injection given every 3 weeks that can be administered in approximately 7 minutes vs 30-to-60-minute infusions with IV, or intravenous, TECENTRIQ which could mean a faster atezolizumab administration option for you and your adult patients.
Let’s start by talking about the product and how to store it.
TECENTRIQ HYBREZA is a sterile, preservative-free solution supplied as a single-dose vial.
TECENTRIQ HYBREZA comes in a single formulation: 1875 milligrams per 15 milliliters supplied in a 20-milliliter single-dose vial.
Store TECENTRIQ HYBREZA vials in the refrigerator at 36 to 46 degrees Fahrenheit, or 2 to 8 degrees Celsius, in the original carton to protect from light until time of use. Do not freeze or shake the vials.
Now let’s go over the steps for preparing the solution but remember to keep in mind any local or institutional guidelines.
To prevent medication errors, make sure to check the vial label to ensure the drug being prepared is subcutaneously administered TECENTRIQ HYBREZA and not intravenously administered atezolizumab. You should also check the expiration date.
TECENTRIQ HYBREZA is a colorless to slightly yellow solution.
Visually inspect the vial for particulate matter and discoloration.
Discard if cloudy, discolored, or visible particles are observed.
Ready-to-use vials should not be diluted. Please note that you should bring the solution to room temperature before administering. The unpunctured vial may be stored at room temperature in ambient light for a maximum of 4 hours prior to the preparation for administration.
To remove the contents of the vial, use a transfer needle attached to a syringe.
An 18-gauge needle is recommended.
Once all the contents are withdrawn, remove the transfer needle from the syringe. Discard the vial and any remaining residual drug.
If the solution will not be injected right away, replace the transfer needle with a syringe closing cap. Do not attach a subcutaneous administration set until the time of administration to avoid needle clogging.
The capped syringe can be stored at room temperature in ambient room lighting for up to 8 hours or in the refrigerator for up to 72 hours. Do not shake or freeze.
Remember, the solution should be administered at room temperature, so if the stored syringe is refrigerated, take it out in advance of the injection
[00:05:00]
with adequate time to warm up. If the syringe still feels cold at injection time, warm it with your hands.
At the time of administration, detach the transfer needle or syringe stopper and discard.
Replace it with a sterile winged subcutaneous administration set with a priming volume no larger than 0.5 milliliters. The suitable injection needle for this solution is between 23 and 25 gauge.
Prime the subcutaneous administration line with the solution to eliminate air, and stop when the fluid reaches the needle. Ensure the syringe contains exactly 15 milliliters of the TECENTRIQ HYBREZA solution after priming by expelling excess volume.
TECENTRIQ HYBREZA is ready for injection. Administer immediately to avoid needle clogging. Do not store the prepared syringe that has been attached to the already-primed subcutaneous administration set.
Now let’s talk about how to administer TECENTRIQ HYBREZA.
Prior to treatment, consider asking your patients to wear loose-fitting clothes like shorts or a skirt to make it easier to access the thigh area during administration.
When it’s time for the injection, ask the patient to sit back in a reclining chair or bed, if possible, to make the thigh area accessible.
Be sure you are in a comfortable position that you can maintain during the approximately 7-minute injection time.
After inserting the needle, the dose should be administered applying continuous pressure on the syringe plunger at a rate of approximately 2 milliliters per minute.
Depending on the patient’s feedback and administrator’s judgment, the administration rate can be adjusted in subsequent doses, if needed.
Remind your patient to sit back and relax, or take this time to talk with the patient and see if they have any questions or concerns.
Once the full dose has been administered, wait briefly before removing the needle to minimize any potential leak back.
Discard any unused portion remaining. The priming volume left in the infusion set must not be administered to the patient. The remaining volume should never be flushed into the injection site.
For subsequent injections, be sure to alternate between the left and right thighs when possible. If other medications are administered subcutaneously during the course of treatment with TECENTRIQ HYBREZA, it’s recommended for them to be injected at sites other than the thighs.
Give each new injection of TECENTRIQ HYBREZA at least 1 inch, or 2.5 centimeters, from the previous site.
Choose an area of healthy skin that is not red, bruised, tender, or hard.
By preparing yourself and the patient for the subcutaneous injection procedure, you can help facilitate a smooth experience.
Thank you for taking the time to watch this video and for all of the work that you do for your patients.
For complete administration information, please review the TECENTRIQ HYBREZA full Prescribing Information.
Please continue to watch for the Important Safety Information.
[00:10:00]
This concludes the Important Safety Information. Thank you again for taking the time to watch this TECENTRIQ HYBREZA administration video.
TIP: The solution should be administered at room temperature (≤25°C or 77°F), so remove the vial from the refrigerator in advance with enough time for it to warm up.
TIP: To best prepare for injection, consider recommending that your patients wear loose-fitting clothes, such as a skirt or shorts. During administration, encourage your patients to sit back and relax, if possible, in a reclining chair. You can also use this time to talk with them about their treatment.
TIP: Give each new injection at least 1 inch from the previous site on healthy skin, and, for the patient’s comfort, never inject areas where the skin is red, bruised, tender, or hard.
TECENTRIQ HYBREZA is a sterile, preservative-free solution supplied as a single-dose vial (NDC 50242-933-01)
Each TECENTRIQ HYBREZA vial is ready to use for 1 subcutaneous injection and should not be diluted.
If the prepared syringe is not for immediate use, do not attach an SC administration set.
NDC=National Drug Code; SC=subcutaneous.
Visualization of vials is illustrative.
IV=intravenous; q4w=every 4 weeks; q3w=every 3 weeks; q2w=every 2 weeks.
TECENTRIQ HYBREZA Prescribing Information. Genentech, Inc.
TECENTRIQ HYBREZA Prescribing Information. Genentech, Inc.
Burotto M, Zvirbule Z, Mochalova A, et al. IMscin001 part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023;34:693-702.
Burotto M, Zvirbule Z, Mochalova A, et al. IMscin001 part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023;34:693-702.
Burotto M, Zvirbule Z, Alvarez R, et al. Brief report: updated data from IMscin001 part 2, a randomized phase III study of subcutaneous versus intravenous atezolizumab in patients with locally advanced or metastatic NSCLC. J Thorac Oncol. Published online May 9, 2024. doi:10.1016/j.jtho.2024.05.005
Burotto M, Zvirbule Z, Alvarez R, et al. Brief report: updated data from IMscin001 part 2, a randomized phase III study of subcutaneous versus intravenous atezolizumab in patients with locally advanced or metastatic NSCLC. J Thorac Oncol. Published online May 9, 2024. doi:10.1016/j.jtho.2024.05.005
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
Cappuzzo F, Zvirbule Z, Korbenfed E, et al. Primary results from IMscin002: A study to evaluate patient- and healthcare professional-reported preferences for atezolizumab subcutaneous vs intravenous for the treatment of non-small cell lung cancer. Presented at: European Lung Cancer Congress; March 20-23, 2024; Prague, Czech Republic.
Cappuzzo F, Zvirbule Z, Korbenfed E, et al. Primary results from IMscin002: A study to evaluate patient- and healthcare professional-reported preferences for atezolizumab subcutaneous vs intravenous for the treatment of non-small cell lung cancer. Presented at: European Lung Cancer Congress; March 20-23, 2024; Prague, Czech Republic.
TECENTRIQ Prescribing Information. Genentech, Inc.
TECENTRIQ Prescribing Information. Genentech, Inc.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.